Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model
Feterl, Marshall, Govan, Brenda, Engler, Cathy, Norton, Robert, and Ketheesan, Natkunam (2006) Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model. International Journal of Antimicrobial Agents, 28 (5). pp. 460-464.
|PDF (Published version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://dx.doi.org/10.1016/j.ijantimicag....
Burkholderia pseudomallei is the causative agent of melioidosis. Standard therapy includes ceftazidime alone or in combination with co-trimoxazole. Tigecycline, a novel agent, has displayed activity against B. pseudomallei. We evaluated the in vivo efficacy of tigecycline using a murine model of melioidosis. Mice were infected with either a high or low virulence B. pseudomallei isolate followed by administration of antibiotics alone or in combination (tigecycline, ceftazidime, tigecycline plus ceftazidime) for 7 days. Bacterial loads were assessed up to 7 days and survival was determined up to 7 days post infection. Tigecycline in combination with ceftazidime was the most effective and conferred the lowest mortality, suggesting the use of this new agent in B. pseudomallei infection.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||infection; Burkholderia pseudomallei; tigecycline; therapy|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1103 Clinical Sciences > 110309 Infectious Diseases @ 80%|
11 MEDICAL AND HEALTH SCIENCES > 1108 Medical Microbiology > 110801 Medical Bacteriology @ 20%
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920109 Infectious Diseases @ 100%|
|Deposited On:||19 Nov 2009 16:02|
|Last Modified:||18 Oct 2013 00:33|
Last 12 Months: 0
|Citation Counts with External Providers:|
Repository Staff Only: item control page